Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

Four months after ditching its lead drug, a small Peninsula biotech with less than $40 million on hand hopes to rev up ...

BioMarin Pharmaceutical BMRN shares ended the last trading session 6.3% higher at $59.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating in a report issued on Tuesday. Other analysts also recently issued research ...

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time to buy.

Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a ...

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...